Zhenfan Yang

发表

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017, The Lancet. Respiratory medicine.

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

M. Ahn, Dong-Wan Kim, J. Yang, 2016, Science Translational Medicine.

EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases

J. Zhao, G. Zhu, W. Zhong, 2016, Cancer Chemotherapy and Pharmacology.

Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.

M. Ahn, Dong-Wan Kim, J. Yang, 2017 .

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.

K. Varnäs, P. Johnström, Xiaolin Zhang, 2015, Journal of medicinal chemistry.

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist

Ziyi Liu, Zhenfan Yang, Xin Zhang, 2022, Journal of Experimental & Clinical Cancer Research.

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

I. Barrett, K. Varnäs, K. Valerie, 2018, Science Advances.

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, S. Chuai, 2017, Clinical Cancer Research.

High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?

G. Zhu, Q. Ji, Lei Zhong, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR G796D mutation mediates resistance to osimertinib

Z. Wang, Xuehua Zhu, Chunyan Wu, 2017, Oncotarget.

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

Yi-long Wu, Jin-Ji Yang, Z. Wang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Matthew Grist, P. Jänne, K. Varnäs, 2016, Clinical Cancer Research.

Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy.

Meizhuo Zhang, J. Zhao, Li Zhang, 2018, Lung cancer.

Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.

M. Ahn, Haiyi Jiang, Dong-Wan Kim, 2016 .

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third‐Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

Yi-long Wu, Jin-Ji Yang, Z. Wang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma

Xubin Huang, H. Eom, W. Kim, 2020 .

Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).

M. Ahn, Haiyi Jiang, Dong-Wan Kim, 2016 .

Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non‐small cell lung cancer

Xia Li, Jinming Yu, L. Xing, 2018, International journal of cancer.

Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants

P. Hu, Ziyi Liu, Kan Chen, 2023, Frontiers in Immunology.

Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer

Jinming Yu, Xiangjiao Meng, L. Xing, 2018, Oncology reports.

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Thoracic cancer.

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

Extended resection of the left atrium, great vessels, or both for locally advanced lung cancer: An experience of 248 cases

Jin-Ji Yang, Qinghua Zhou, Zhenfan Yang, 2000 .

Abstract 3081: DZD9008, an oral, wild type selective EGFR inhibitor for the treatment of non-small-cell lung cancer with Exon20 insertion and other activating mutations

Yan Xu, Lin Zhang, Zhenfan Yang, 2019, Experimental and Molecular Therapeutics.